- Home
- PCH vs IMVT Comparison
PCH vs IMVT Comparison
Compare PCH & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCH
- IMVT
- Stock Information
- Founded
- PCH 1903
- IMVT 2018
- Country
- PCH United States
- IMVT United States
- Employees
- PCH N/A
- IMVT N/A
- Industry
- PCH Real Estate Investment Trusts
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCH Real Estate
- IMVT Health Care
- Exchange
- PCH Nasdaq
- IMVT Nasdaq
- Market Cap
- PCH 3.3B
- IMVT 2.7B
- IPO Year
- PCH N/A
- IMVT N/A
- Fundamental
- Price
- PCH $41.95
- IMVT $16.00
- Analyst Decision
- PCH Strong Buy
- IMVT Buy
- Analyst Count
- PCH 6
- IMVT 10
- Target Price
- PCH $49.67
- IMVT $33.38
- AVG Volume (30 Days)
- PCH 578.8K
- IMVT 1.7M
- Earning Date
- PCH 11-03-2025
- IMVT 11-06-2025
- Dividend Yield
- PCH 4.29%
- IMVT N/A
- EPS Growth
- PCH 15.06
- IMVT N/A
- EPS
- PCH 0.53
- IMVT N/A
- Revenue
- PCH $1,056,523,000.00
- IMVT N/A
- Revenue This Year
- PCH $4.14
- IMVT N/A
- Revenue Next Year
- PCH $3.80
- IMVT N/A
- P/E Ratio
- PCH $79.35
- IMVT N/A
- Revenue Growth
- PCH N/A
- IMVT N/A
- 52 Week Low
- PCH $36.82
- IMVT $12.72
- 52 Week High
- PCH $48.12
- IMVT $32.10
- Technical
- Relative Strength Index (RSI)
- PCH 54.80
- IMVT 50.79
- Support Level
- PCH $39.10
- IMVT $15.81
- Resistance Level
- PCH $42.90
- IMVT $17.15
- Average True Range (ATR)
- PCH 0.91
- IMVT 0.73
- MACD
- PCH 0.29
- IMVT 0.10
- Stochastic Oscillator
- PCH 75.42
- IMVT 57.98
About PCH PotlatchDeltic Corporation
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.